Feb 4, 2009 - Teva Pharmaceutical Industries Ltd. today announced that the Medicines and Healthcare products Regulatory Agency has approved an expanded label for COPAXONE® (glatiramer acetate injection) to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple sclerosis (MS).
The details can be read here.
No comments:
Post a Comment